"Due to the growing number of heart failure patients not amenable to revascularization techniques such as CABG, the CO2 TMR and stem cell therapy has significant potential as an effective procedure for seriously ill coronary artery disease patients," said Doctor Klein. "Our research has demonstrated that CO2 TMR can initiate an internal angiogenic response, which is critical when we are striving for tissue regeneration. At our institution we have performed more than thirty CO2 TMR plus stem cell procedures. We believe that when autologous, bone marrow-derived stem cells are injected into the patient's heart around the laser channel, the mediators released in response to the laser procedure attract the bone marrow cells, also known as the homing effect, which starts a cascade of events leading to an angiogenic and vasogenic response that can improve cardiac function in heart failure patients."

On September 25, Edwards Lifesciences is hosting a Center of Excellence program at the Pepin Heart Hospital & Dr. Kiran C. Patel Research Institute, in Tampa, Florida, which will feature a presentation on TMR by Dr. Ernesto Jimenez. "These programs provide an educational opportunity for physicians to learn to use PLC Medical's CO2 Heart Laser to perform CO2 transmyocardial revascularization," stated Mark R. Tauscher, president and CEO of PLC Medical Systems, Inc. "We are very pleased to enable Dr. Klein to share his cutting edge research and experiences with the members of the North American cardiac community."

About PLC Medical Systems, Inc.

PLC Medical Systems, Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Headquartered in Franklin, Mass., PLC pioneered the CO2 Heart Laser System, which cardiac surgeons use to perform CO2 transmyocardial revascularization (TMR) to alleviate symptoms of severe angina. CO2 TMR offers a treatment option for angina patients who suffer from severe coronary artery disease. Coronary artery disease is expected to increase as the worldwide population continues to age. Working with leading researchers and premier heart centers around the world, PLC developed the CO2 Heart Laser, which is the world's first TMR angina relief device approved by both the U.S. Food and Drug Administration and Japanese MHLW. Additional company information can be found at http://www.plcmed.com.

About Miltenyi Biotec

Miltenyi Biotec, founded in 1989, is a diversified biotechnology company, offering comprehensive solutions for basic, biomedical, and clinical research. The company develops, produces, and markets state-of-the-art products and services for cell separation, cell analysis, cell culture, molecular biology, and clinical research applications. With subsidiaries and distributors around the world, the company has more than 900 employees. Additional company information can be found at http://www.miltenyi.com.

This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including preliminary data demonstrating improved results from the use of TMR plus stem cells may not be supported in a broader patient population, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, we may be unable to convince health care professionals and third party payers of the medical and economic benefits of the CO2 Heart Lasers, and there can be no assurance that all payers will reimburse health care providers who perform TMR procedures or that reimbursement, if provided, will be adequate, and additional risk factors described in our Report on Form 10-K for the year ended December 31, 2005, and our other SEC reports.